XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.2
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES - Additional Information (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
customer
Jun. 30, 2024
USD ($)
customer
Jun. 30, 2025
USD ($)
customer
segment
Jun. 26, 2025
segment
Jun. 30, 2024
USD ($)
customer
Sep. 30, 2024
USD ($)
customer
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Net loss from continuing operations $ 3,647,914 $ (1,883,292) $ 9,585,822   $ 3,502,166  
Operating cash flow     9,141,688   $ 10,323,243  
Cash and cash equivalents 4,727,677   4,727,677     $ 5,852,363
Excess of FDIC insurance limit 4,700,000   $ 4,700,000      
Number of reportable segments | segment     2 3    
Transfers from Level 2 to Level 1, Assets 0   $ 0      
Transfers from Level 1 to Level 2, Assets 0   0      
Transfers from Level 2 to Level 1, Liabilities 0   0      
Transfers from Level 1 to Level 2, Liabilities $ 0   0      
Transfers Into Level 3, Liabilities     0      
Transfers out of Level 3, Liabilities     $ 0      
Customer Concentration Risk | Total Revenue | DNA Tagging and Security Products            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Number of customers | customer     2   1  
Customer Concentration Risk | Total Revenue | MDx Testing Services            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Number of customers | customer   1     1  
Customer Concentration Risk | Total Revenue | Therapeutic DNA Production Services and DNA Tagging and Security Products and Services            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Number of customers | customer 2          
Customer Concentration Risk | Total Revenue | One customer            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage         12.00%  
Customer Concentration Risk | Total Revenue | One customer | DNA Tagging and Security Products            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage     23.00%      
Customer Concentration Risk | Total Revenue | One customer | MDx Testing Services            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage   46.00%     29.00%  
Customer Concentration Risk | Total Revenue | One customer | Therapeutic DNA Production            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage     26.00%      
Number of customers | customer     1      
Customer Concentration Risk | Total Revenue | Two customer | DNA Tagging and Security Products            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage     12.00%      
Customer Concentration Risk | Total Revenue | Two customers | DNA Tagging and Security Products            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage 12.00%          
Customer Concentration Risk | Total Revenue | Two customers | Therapeutic DNA Production            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage 53.00%          
Customer Concentration Risk | Accounts Receivable            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Number of customers | customer     3     5
Customer Concentration Risk | Accounts Receivable | Three customers            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage     82.00%      
Customer Concentration Risk | Accounts Receivable | Five Customers            
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES            
Concentration risk percentage           75.00%